AC Immune 관리

관리 기준 확인 2/4

AC Immune CEO는 Andrea Pfeifer, Apr2003 에 임명되었습니다 의 임기는 21.58 년입니다. 총 연간 보상은 CHF 2.65M, 21.8% 로 구성됩니다. 21.8% 급여 및 78.2% 보너스(회사 주식 및 옵션 포함). 는 € 7.79M 가치에 해당하는 회사 주식의 2.45% 직접 소유합니다. 7.79M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 6.6 년입니다.

주요 정보

Andrea Pfeifer

최고 경영자

CHF 2.7m

총 보상

CEO 급여 비율	21.8%
CEO 임기	21.6yrs
CEO 소유권	2.4%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	6.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Andrea Pfeifer 의 보수는 AC Immune 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-CHF 40m
Jun 30 2024	n/a	n/a	-CHF 61m
Mar 31 2024	n/a	n/a	-CHF 55m
Dec 31 2023	CHF 3m	CHF 578k	-CHF 54m
Sep 30 2023	n/a	n/a	-CHF 68m
Jun 30 2023	n/a	n/a	-CHF 67m
Mar 31 2023	n/a	n/a	-CHF 69m
Dec 31 2022	CHF 2m	CHF 558k	-CHF 71m
Sep 30 2022	n/a	n/a	-CHF 73m
Jun 30 2022	n/a	n/a	-CHF 76m
Mar 31 2022	n/a	n/a	-CHF 75m
Dec 31 2021	CHF 2m	CHF 530k	-CHF 73m
Sep 30 2021	n/a	n/a	-CHF 71m
Jun 30 2021	n/a	n/a	-CHF 74m
Mar 31 2021	n/a	n/a	-CHF 71m
Dec 31 2020	CHF 2m	CHF 520k	-CHF 62m
Sep 30 2020	n/a	n/a	-CHF 62m
Jun 30 2020	n/a	n/a	-CHF 25m
Mar 31 2020	n/a	n/a	-CHF 26m
Dec 31 2019	CHF 2m	CHF 510k	CHF 45m
Sep 30 2019	n/a	n/a	CHF 50m
Jun 30 2019	n/a	n/a	CHF 18m
Mar 31 2019	n/a	n/a	CHF 24m
Dec 31 2018	CHF 2m	CHF 455k	-CHF 51m
Sep 30 2018	n/a	n/a	-CHF 32m
Jun 30 2018	n/a	n/a	-CHF 27m
Mar 31 2018	n/a	n/a	-CHF 29m
Dec 31 2017	CHF 2m	CHF 404k	-CHF 26m

보상 대 시장: Andrea 의 총 보상 ($USD 3.00M )은 German 시장( $USD 1.03M ).

보상과 수익: 회사가 수익성이 없는 동안 Andrea 의 보상이 증가했습니다.

CEO

Andrea Pfeifer (67 yo)

21.6yrs

테뉴어

CHF 2,650,000

보상

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrea Pfeifer	Co-Founder	21.6yrs	CHF 2.65m	2.45% € 7.8m
Christopher Roberts	CFO & VP of Finance	2.6yrs	데이터 없음	0.013% € 40.6k
Piergiorgio Donati	Chief Technical Operations Officer	5.8yrs	데이터 없음	0.025% € 78.9k
Jean-Fabien Monin	Chief Administrative Officer	9.3yrs	데이터 없음	0.32% € 1.0m
Howard Donovan	Chief HR Officer	2.6yrs	데이터 없음	0.020% € 64.8k
Madiha Derouazi	Chief Scientific Officer	less than a year	데이터 없음	0.0032% € 10.2k
Gary Waanders	Senior VP of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Alexandre Caratsch	General Counsel	no data	데이터 없음	데이터 없음
Julian Snow	VP of U.S. Finance & Corporate Development	2.6yrs	데이터 없음	데이터 없음
David Hickman	Head of AD - SME	14.8yrs	데이터 없음	데이터 없음
Joseph Wettstein	Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer	8.8yrs	데이터 없음	데이터 없음
Oliver Sol	VP & Head of Clinical Development	no data	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: IMR 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andrea Pfeifer	Co-Founder	8.5yrs	CHF 2.65m	2.45% € 7.8m
Jean-Marie Lehn	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Claude Nicolau	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Douglas Williams	Independent Non-Executive Chairman	6.6yrs	CHF 179.00k	0.039% € 125.3k
Alf E. Lindberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Detlev Riesner	Member of Scientific Advisory Board	no data	CHF 5.00k	데이터 없음
Fred Van Leuven	Member of Scientific Advisory Board	no data	CHF 105.00k	데이터 없음
I. Rosenberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
M. Monsigny	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
E. Lestringant	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Monika Butler	Independent Vice Chair	3.1yrs	CHF 163.00k	0.0092% € 29.5k
Andreas Monsch	Head of Clinical Advisory Board	no data	데이터 없음	데이터 없음

6.6yrs

평균 재임 기간

74.5yo

평균 연령

경험이 풍부한 이사회: IMR 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

AC Immune 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

AC Immune SA, Annual General Meeting, Jun 20, 2024

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

AC Immune SA Announces Executive Changes

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

New major risk - Revenue and earnings growth

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

New major risk - Revenue and earnings growth

AC Immune SA Announces Executive Changes

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

New 90-day high: €5.57

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: €5.17

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

AC Immune Sa Appoints Carl H. June as Board of Directors

AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer

Revenue beats expectations

Third quarter 2020 earnings released: CHF0.26 loss per share

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

New 90-day low: €3.83

AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

New 90-day low: €4.25

First half earnings released

New 90-day high - €7.95

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령